2,2-Dimethyl-adamant-1-ylbromid | 33954-19-7

• 英文名称: 2,2-Dimethyl-adamant-1-ylbromid
• 英文别名: Dimethyladamantyl bromide；1-bromo-2,2-dimethyladamantane
• CAS: 33954-19-7
• 化学式: C₁₂H₁₉Br
• 分子量: 243.187
• InChiKey: KNXWQMXZCMXQIN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.5
• 重原子数：
  13
• 可旋转键数：
  0
• 环数：
  4.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  0
• 氢给体数：
  0
• 氢受体数：
  0

反应信息

• 作为反应物：
  描述：

  1-溴-3,5-二甲基金刚烷 、 3-溴丙烯 、 、 2,2-Dimethyl-adamant-1-ylbromid 、 1-dichlorosilyl-2-trichlorosilylethane 在 锌 ice acetone 、 水 、 正戊烷 、 乙醇 、 magnesium sulfate 、 1,3-Dimethyl-5-prop-2-enyladamantane 作用下， 以 正戊烷 为溶剂， -10.0~100.0 ℃ 、6.67 kPa 条件下， 反应 21.5h， 以yielding 53.54 g (51%), bp. 157-158° C./<0.5 mbar的产率得到1,1,1,4,4-Pentachloro-7-(3,5-dimethyladamantyl)-1,4-disilaheptane
  参考文献：
  名称：

  Nanoparticle containing siloxane polymers

  摘要：

  一种用于制备半导体光电子聚合物组合物的方法，包括以下步骤：提供至少一种二硅烷单体，该单体通过同源或共聚反应形成（共）聚合物，然后与纳米颗粒结合形成聚合物组合物。该含纳米颗粒的组合物具有高折射率或介电常数等优异性能。

  公开号：

  US07833820B2

文献信息

• Methods for treating neuropsychiatric disorders with nmda receptor antagonists
  申请人：——

  公开号：US20040122090A1

  公开（公告）日：2004-06-24

  The present invention relates to compositions and methods for treating a human patient afflicted with a neuropsychiatric disorder. Specifically, the invention provides for compositions and methods of modulating or antagonizing the activity of neuronal NMDA receptors, wherein such antagonistic activity is capable of modulating the glutamate induced excitatory response of the neurons, thereby inhibiting an excitotoxic effect, promoting a neurotrophic effect, and thereby providing a therapeutic effect that treats the neuropsychiatric disorder.

  本发明涉及用于治疗患有神经精神障碍的人类患者的组合物和方法。具体而言，本发明提供了用于调节或拮抗神经元NMDA受体活性的组合物和方法，其中这种拮抗活性能够调节神经元的谷氨酸诱导的兴奋反应，从而抑制兴奋毒性效应，促进神经营养效应，并提供治疗效果以治疗神经精神障碍。
• Aminoadamantane derivatives as therapeutic agents
  申请人：Wang Yuqiang

  公开号：US20060106222A1

  公开（公告）日：2006-05-18

  The present invention provides novel aminoadamantane derivatives, methods of making the derivatives, compositions including the novel aminoadamantane derivatives, and methods for the treatment and prevention of neurological diseases using the derivatives and compositions There are a variety of neurological disorders that can be treated using the present invention, including, for example, the following: neurological disorders arising from trauma, ischemic or hypoxic conditions that can be treated include stroke, hypoglycemia, cerebral ischemia, cardiac arrest, spinal cord trauma, head trauma, perinatal hypoxia, cardiac arrest and hypoglycemic neuronal damage; neurodegenerative disorders such as epilepsy, Alzheimer's disease, Huntington's disease Parkinsonism, and amyotrophic lateral sclerosis; other diseases or disorders such as convulsion, pain, depression, anxiety, schizophrenia, muscle spasms, migraine headaches, urinary incontinence, nicotine withdrawal, opiate tolerance and withdrawal, emesis, brain edema, tardive dyskinesia, AIDS-induced dementia, ocular damage, retinopathy, cognitive disorders, and neuronal injury associated with HIV-infection such as dysfunction in cognition, movement and sensation.

  本发明提供了新型氨基金刚烷衍生物、制备该衍生物的方法、包括新型氨基金刚烷衍生物的组合物、以及使用该衍生物和组合物治疗和预防神经系统疾病的方法。可以使用本发明治疗各种神经系统疾病，包括但不限于以下疾病：因创伤、缺血或缺氧引起的神经系统疾病，如中风、低血糖、脑缺血、心脏骤停、脊髓创伤、头部创伤、围产期缺氧、心脏骤停和低血糖神经损伤；神经退行性疾病，如癫痫、阿尔茨海默病、亨廷顿病、帕金森综合征和肌萎缩性侧索硬化；其他疾病或疾病，如惊厥、疼痛、抑郁症、焦虑症、精神分裂症、肌肉痉挛、偏头痛、尿失禁、尼古丁戒断、鸦片耐受性和戒断、呕吐、脑水肿、迟发性运动障碍、艾滋病相关痴呆、眼损伤、视网膜病变、认知障碍以及与HIV感染相关的神经损伤，如认知、运动和感觉功能障碍。
• AMINOADAMANTANE DERIVATIVES AS THERAPEUTIC AGENTS
  申请人：Wang Yuqiang

  公开号：US20080183003A1

  公开（公告）日：2008-07-31

  The present invention provides novel aminoadamantane derivatives, methods of making the derivatives, compositions including the novel aminoadamantane derivatives, and methods for the treatment and prevention of neurological diseases using the derivatives and compositions. There are a variety of neurological disorders that can be treated using the present invention, including, for example, the following: neurological disorders arising from trauma, ischemic or hypoxic conditions that can be treated include stroke, hypoglycemia, cerebral ischemia, cardiac arrest, spinal cord trauma, head trauma, perinatal hypoxia, cardiac arrest and hypoglycemic neuronal damage; neurodegenerative disorders such as epilepsy, Alzheimer's disease, Huntington's disease Parkinsonism, and amyotrophic lateral sclerosis; other diseases or disorders such as convulsion, pain, depression, anxiety, schizophrenia, muscle spasms, migraine headaches, urinary incontinence, nicotine withdrawal, opiate tolerance and withdrawal, emesis, brain edema, tardive dyskinesia, AIDS-induced dementia, ocular damage, retinopathy, cognitive disorders, and neuronal injury associated with HIV-infection such as dysfunction in cognition, movement and sensation.

  本发明提供了新型氨基金刚烷衍生物，制备这些衍生物的方法，包括这些新型氨基金刚烷衍生物的组合物，以及使用这些衍生物和组合物治疗和预防神经系统疾病的方法。可以使用本发明治疗各种神经系统疾病，包括以下疾病：因创伤、缺血或缺氧引起的神经系统疾病，包括中风、低血糖、脑缺血、心脏骤停、脊髓损伤、头部损伤、围产期缺氧、心脏骤停和低血糖神经元损伤；神经退行性疾病，如癫痫、阿尔茨海默病、亨廷顿病帕金森综合症和肌萎缩性侧索硬化；其他疾病或疾病，如惊厥、疼痛、抑郁、焦虑、精神分裂症、肌肉痉挛、偏头痛、尿失禁、尼古丁戒断、阿片类药物耐受性和戒断、呕吐、脑水肿、迟发性运动障碍、艾滋病相关痴呆、眼损伤、视网膜病变、认知障碍以及与HIV感染相关的神经元损伤，如认知、运动和感觉功能障碍。
• Novel nanoparticle containing siloxane polymers
  申请人：Rantala Juha

  公开号：US20080188032A1

  公开（公告）日：2008-08-07

  A method of producing a polymer composition for semiconductor optoelectronics, comprising the steps of providing at least one type of disilane monomer which is homo- or copolymerized to form a (co)polymer and then combined with nanoparticles to provide a polymer composition. The nanoparticle containing composition has excellent properties with high refractive index or dielectric constant.

  一种用于制造半导体光电子聚合物组分的方法，包括以下步骤：提供至少一种二硅烷单体，该单体经过同聚或共聚形成（共）聚合物，然后与纳米颗粒结合以提供聚合物组分。含有纳米颗粒的组分具有高折射率或介电常数的优异性能。
• Organo functionalized silane monomers and siloxane polymers of the same
  申请人：Rantala T. Juha

  公开号：US20060293482A1

  公开（公告）日：2006-12-28

  A thin film comprising a composition obtained by polymerizing a monomer having the formula I: wherein: R 1 is a hydrolysable group, R 2 is an organic crosslinking group, a reactive cleaving group or a polarizability reducing organic group, and R 3 is a bridging linear or branched bivalent hydrocarbyl group to form a siloxane material. The organo-functionalized molecule is capable of further reacting in the matrix so as to undergo cross-linking, cleaving or combination of both. The present invention provides excellent chemical resistance and very low chemical adsorption behavior due to high cross-linking bridging group density.

  一种薄膜，包括由聚合式单体制备的组合物，该聚合式单体具有式I：其中：R1为可水解基团，R2为有机交联基团、反应性断裂基团或极化还原有机基团，而R3为桥联线性或分支二价碳氢基团，以形成硅氧烷材料。有机官能化分子能够在基质中进一步反应，以经历交联、断裂或两者的组合。本发明由于具有高交联桥联基团密度，提供了优异的化学抗性和非常低的化学吸附行为。